RecruitingPriority 2 · High priorityNCT05934513
A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Plain-language summary
This trial is testing GFH009 for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years to 75 Years years
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
GFH009 (DRUG): patients are planned to be administrated with GFH009 every week in a 21 days cycle, intravenous infusion
GFH009
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details